Melexis Q4 and FY 2016 results - Melexis growth doubles

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
149
Melexis Q4 and FY 2016 results - Melexis growth doubles market growth

Intermediate declaration by the Board of Directors Ieper, Belgium - February 8th, 2017, 07.00 hrs CET

For the full year 2016 , sales were 456.3 million EUR, an increase of 14% compared to the previous year.  The EUR/USD exchange rate evolution had no impact compared to 2015.  Gross margin was 208.5 million EUR, an increase of 9% compared to 2015. R&D expenses were 14.0% of sales, G&A was at 4.6% of sales and Selling was at 2.1% of sales. The operating result was 114.4 million EUR, an increase of 6% compared to last year.  Net income was 96.3 million EUR, 2.38 EUR per share, a decrease of 3% compared to 99.1 million EUR or 2.45 EUR per share in 2015.

Sales for the fourth quarter of 2016 were 120.0 million EUR, an increase of 17% compared to the same quarter of the previous year and an increase of 5% compared to the previous quarter. The EUR/USD exchange rate evolution had no impact compared to the same quarter of last year and a positive impact of 1% compared to the previous quarter. Gross margin was 55.2 million EUR, an increase of 16% compared to the same quarter of last year and an increase of 4% compared to the previous quarter.  R&D expenses were 14.2% of sales, G&A was at 4.9% of sales and Selling was at 2.4% of sales. The operating result was 29.4 million EUR, an increase of 23% compared to the same quarter of last year and a decrease of 1% compared to the previous quarter. Net income was 25.1 million EUR or 0.62 EUR per share, an increase of 14% compared to 22.0 million EUR or 0.54 EUR per share in the fourth quarter of 2015 and flat compared to the previous quarter.

Dividend The Board of Directors approved on February 3rd 2017 to propose to the Annual Shareholder meeting to pay out over the result of 2016 a total dividend of EUR 2.00 gross per share. This amount contains an interim dividend of EUR 1.30 per share which was paid in October 2016 and a final dividend of EUR 0.70 per share which will be payable after approval of the Annual Shareholders meeting.  The Melexis shares will start trading ex coupon on April 25, 2017 (opening of the market). The record date is April 26, 2017 (closing of the market) and the dividend will be payable as from April 27, 2017.

Outlook Melexis expects sales in the first quarter of 2017 to be around the level of 125 million EUR. For the full year 2017, Melexis expects sales growth to be between 11% and 15%, a gross profit margin around 45% and an operating margin around 25%, all taking into account a EUR/USD exchange rate of 1.07.

Business comment - Françoise Chombar, CEO: "Melexis proudly presents its full year 2016 results: with a year over year growth of 14%, a gross margin close to 46% and an operating margin of 25%, we exceed our outlook given at the beginning of the year. Based on the latest market data¹, Melexis 2016 growth doubles automotive semiconductor growth, with all regions contributing. The last quarter of the year was exceptionally strong: typical negative inventory corrections did not occur, the strong demand in all product lines contributed to a sequential sales growth of 5% and a year over year growth of 17%. The main growth drivers, both in the last quarter and the full year continue to be our magnetic sensor product lines, pressure sensors and fan drivers. On average, every new car in the world now carries 8 chips of Melexis. It is with confidence we look forward to 2017: top line growth is expected to be supported by many new and existing products in multiple product lines such as magnetic sensors, sensor interfaces, optical sensors, pressure sensors,  fan drivers, BLDC and LIN. In order to support that growth, Melexis continues to invest in R&D, sales & marketing and automation. Sales to automotive customers represented 88% of total sales in the fourth quarter and 89% of total sales for the full year 2016. The portion of standard product (ASSPs) sales represented 61% of total sales, both in the fourth quarter and full year 2016.'' ¹Strategy Analytics, January 2017

The statutory auditor BDO Bedrijfsrevisoren Burg. Ven. CVBA, has confirmed that their audit procedures, which have been substantially completed, have not revealed material adjustments which would have to be made to the accounting information included in this press release.

Financial Calendar

  • Annual Shareholders Meeting: April 20, 2017
  • Publication Q1 2017 Results: April 20, 2017
  • Dividend pay date: April 27, 2017 (ex coupon on April 25, 2017)
  • Analyst Day: May 3, 2017
  • Publication Q2/HY1 2017 Results: August 2, 2017
  • Publication Q3 2017 Results: October 25, 2017
  • Publication FY 2017 Results: February 7, 2018

The company's results will be discussed in a conference call on Wednesday, February 8 th , 2017 at 17 hrs CET. The conference call will be in English. You have to register for this conference call in advance. You can register by clicking on the following link and filling out the requested information: https://eventreg3.conferencing.com/inv/reg.ht...onf=369864   Conference ID: 961215.

After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes all participants must register individually if they wish to join the call.

A replay number for this call is available for 7 days after the end of the conference call. The replay number for this call is +32 2 290 17 05, access code: 961215.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...de4fc0fbb2

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 3

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 2

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackRock's Strong Performance Lifts Market Spirits

Updated Category News Views 62

BlackRock's Earnings Impact Future Market Trends As investors eagerly glance at the market, recent trends suggest a positive shift, particularly with BlackRock, Inc. reporting remarkable third-quarter earnings. The upbeat results have lifted not only the company’s profile but also the sentiments across various sectors. Market Overview In recent trading sessions, U.S....

Continue Reading
Endo Unveils I Got Somebody Campaign for Peyronie's Disease

Updated Category News Views 648

Endo Launches Awareness Campaign for Peyronie’s Disease Endo, Inc. (OTCQX: NDOI) has recently introduced a compelling initiative titled I Got Somebody. This campaign is designed to encourage men to confront their feelings of embarrassment around Peyronie's disease (PD) and to have open discussions about this condition which affects many. The company aims to empower men...

Continue Reading
Investigation Launched into Aehr Test Systems for Investors' Losses

Updated Category News Views 218

Investigation into Aehr Test Systems, Inc. Focused on Investor Protection The Law Offices of Frank R. Cruz are actively investigating Aehr Test Systems, Inc. (NASDAQ: AEHR) in light of significant concerns raised regarding the company’s adherence to federal securities laws. This investigation comes as a response to alarming financial disclosures made public by the...

Continue Reading
SeaStar Medical Advances adult AKI Treatment with Stanford

Updated Category News Views 69

SeaStar Medical Welcomes Stanford Medicine's Enrollment in AKI Trial SeaStar Medical Holding Corporation (NASDAQ: ICU) is excited to announce that Stanford Medicine will begin actively enrolling subjects in its pivotal trial focused on Adult Acute Kidney Injury (AKI). This collaboration emphasizes the company’s mission to enhance treatment options for patients...

Continue Reading
Exciting Updates on Class A Shares for Investors and Stakeholders

Updated Category News Views 163

Important Distribution Announcement for Class A Shareholders In a recent announcement, Real Estate Split Corp. (TSX: RS) has excitedly shared plans to distribute dividends to Class A shareholders. This distribution not only signifies growth but also represents the company's commitment to providing value to its investors. Key Dates for the Upcoming Distribution For...

Continue Reading